L.DrummondR
"Initiation of the BELIEVE study is a significant milestone in our journey to advance bimagrumab as a potentially transformational new treatment for obesity that can produce significant fat loss along with an increase in muscle mass, which provides better quality weight loss overall," said Kenneth Attie, M.D., Chief Medical Officer at Versanis
The Diabetes Control and Complications Trial (DCCT), a prospective randomized controlled trial of intensive (mean A1C about 7% [53 mmol/mol]) versus standard (mean A1C about 9% [75 mmol/mol]) glycemic control in patients with type 1 diabetes, showed definitively that better glycemic control is associated with 5076% reductions in rates of development and progression of microvascular (retinopathy, neuropathy, and diabetic kidney disease) complications
Some dont
Unfortunately, dietary surveys consistently show that many adults don't consume adequate magnesium, and this deficiency risk increases with reduced caloric intake on semaglutide
These treatments tend to sit at the lower end of the price range